0001209191-21-017304.txt : 20210303 0001209191-21-017304.hdr.sgml : 20210303 20210303190017 ACCESSION NUMBER: 0001209191-21-017304 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210301 FILED AS OF DATE: 20210303 DATE AS OF CHANGE: 20210303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pellini Michael J CENTRAL INDEX KEY: 0001402017 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 21711461 MAIL ADDRESS: STREET 1: 222 DUTTON MILL RD CITY: WILLISTOWN STATE: PA ZIP: 19380 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-01 0 0001478320 Adaptive Biotechnologies Corp ADPT 0001402017 Pellini Michael J C/O ADAPTIVE BIOTECHNOLOGIES CORP. SUITE 200 SEATTLE WA 98102 1 0 0 0 Common Stock 2021-03-01 4 M 0 20000 6.55 A 20000 D Common Stock 2021-03-01 4 S 0 20000 57.80 D 0 D Stock Option (Right to Buy) 6.55 2021-03-01 4 M 0 20000 0.00 D 2028-02-07 Common Stock 20000 55000 D The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.75 to 58.19, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The options vested with respect to 1/4 of such shares on February 7, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. /s/ Michael Pellini by Eric L. Billings, attorney-in-fact 2021-03-03